Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations

INTRODUCTION: It has been recognized that increasing body mass index (BMI) is associated with improved outcome from immune checkpoint inhibitors (ICIs) in patients with various malignancies including non-small cell lung cancer (NSCLC). However, it is unclear whether baseline BMI may influence outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortellini, Alessio, Ricciuti, Biagio, Vaz, Victor R, Soldato, Davide, Alessi, Joao V, Dall’Olio, Filippo G, Banna, Giuseppe L, Muthuramalingam, Sethupathi, Chan, Samuel, Majem, Margarita, Piedra, Aida, Lamberti, Giuseppe, Andrini, Elisa, Addeo, Alfredo, Friedlaender, Alex, Facchinetti, Francesco, Gorría, Teresa, Mezquita, Laura, Hoton, Delphine, Valerie, Lacroix, Nana, Frank Aboubakar, Artingstall, James, Comins, Charles, Di Maio, Massimo, Caglio, Andrea, Cave, Judith, McKenzie, Hayley, Newsom-Davis, Thomas, Evans, Joanne S, Tiseo, Marcello, D'Alessio, Antonio, Fulgenzi, Claudia A M, Besse, Benjamin, Awad, Mark M, Pinato, David J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852707/
https://www.ncbi.nlm.nih.gov/pubmed/35173031
http://dx.doi.org/10.1136/jitc-2021-004374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852707/
https://www.ncbi.nlm.nih.gov/pubmed/35173031
http://dx.doi.org/10.1136/jitc-2021-004374

Ejemplares similares